Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis

Sombat Treeprasertsuk, Marina G. Silveira, Janice L. Petz, Keith Lindor

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94% were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7% and 0.8%, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47% of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.

Original languageEnglish (US)
Pages (from-to)375-381
Number of pages7
JournalAmerican Journal of Therapeutics
Volume18
Issue number5
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Diphosphonates
Osteoporosis
Bone Density
Femur
Spine
zoledronic acid
pamidronate
Prospective Studies

Keywords

  • bone disease
  • parenteral bisphosphonates
  • primary biliary cirrhosis
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. / Treeprasertsuk, Sombat; Silveira, Marina G.; Petz, Janice L.; Lindor, Keith.

In: American Journal of Therapeutics, Vol. 18, No. 5, 09.2011, p. 375-381.

Research output: Contribution to journalArticle

Treeprasertsuk, Sombat ; Silveira, Marina G. ; Petz, Janice L. ; Lindor, Keith. / Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. In: American Journal of Therapeutics. 2011 ; Vol. 18, No. 5. pp. 375-381.
@article{0a1ded47ff52452f9405ec406c7799fe,
title = "Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis",
abstract = "We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94{\%} were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9{\%} and 0.4{\%}, respectively. Eight patients (47{\%}) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7{\%} and 0.8{\%}, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47{\%} of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.",
keywords = "bone disease, parenteral bisphosphonates, primary biliary cirrhosis, treatment",
author = "Sombat Treeprasertsuk and Silveira, {Marina G.} and Petz, {Janice L.} and Keith Lindor",
year = "2011",
month = "9",
doi = "10.1097/MJT.0b013e3181d7e1d3",
language = "English (US)",
volume = "18",
pages = "375--381",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis

AU - Treeprasertsuk, Sombat

AU - Silveira, Marina G.

AU - Petz, Janice L.

AU - Lindor, Keith

PY - 2011/9

Y1 - 2011/9

N2 - We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94% were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7% and 0.8%, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47% of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.

AB - We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94% were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7% and 0.8%, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47% of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.

KW - bone disease

KW - parenteral bisphosphonates

KW - primary biliary cirrhosis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=80052706885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052706885&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181d7e1d3

DO - 10.1097/MJT.0b013e3181d7e1d3

M3 - Article

C2 - 20460985

AN - SCOPUS:80052706885

VL - 18

SP - 375

EP - 381

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 5

ER -